Skip to main content

Table 1 Mean Index Scores By Baseline Clinical Parameters

From: A brief symptom index for advanced renal cell carcinoma

  Karnofsky rating 2   
  90 (n = 113) 80 (n = 45) 70 (n = 30) F (post-hoc)4 Adjacent category mean differences & effect sizes
Index score 1 24.76 (sd = 5.62) 22.89 (sd = 6.84) 18.34 (sd = 4.65) F(2, 185) = 14.67***
80,90 > 70
1.87 (0.30), 4.55 (0.73)
  No. of metastatic sites   
  0 or 1 site (n = 72) 2 or more sites (n = 116) t Mean difference & effect size
Index score 24.81 (sd = 5.57) 22.34 (sd = 6.42) t(186) = 2.69** 2.47 (0.40)
  Risk group 3   
  Favorable (F) (n = 47) Intermediate (I) (n = 95) Poor (P) (n = 41) F (post-hoc)4 Adjacent category mean differences & effect sizes
Index score 26.96 (sd = 3.82) 23.35 (sd = 6.20) 19.47 (sd = 6.06) F(2, 180) = 19.18***
F > I > P
3.61 (0.58), 3.88 (0.63)
  1. Note. 1Higher score, indicates fewer symptoms and better well-being. 290 = Able to carry on normal activity, minor signs or symptoms of disease. 80 = Normal activity with effort, some signs or symptoms of disease. 70 = Cares for self, unable to carry on normal activity or do active work. 3Based on pretreatment features associated with shorter survival. These include: low Karnofsky rating (< 80%), high lactate dehydrogenase level (≥ 1.5 times upper limit of normal), low hemoglobin level (≤ lower limit of normal), high corrected serum calcium (≥ 10 mg/dL), and absence of nephrectomy. Favorable risk = 0 risk factors present. Intermediate risk = 1–2 risk factors present. Poor risk = 3 or more risk factors present. 4Pairwise post-hoc comparisons made using least significant difference test.
  2. **p < .01 ***p < .001